Document is current
Any future updates will be listed below
-
Authors
Simpson, Eric L. https://orcid.org/0000-0003-0853-0252
Hebert, Adelaide A. https://orcid.org/0000-0002-9167-5729
Browning, John https://orcid.org/0000-0002-3708-2252
Serrao, Rocco T.
Sofen, Howard https://orcid.org/0000-0001-7789-6915
Brown, Philip M.
Piscitelli, Stephen C. https://orcid.org/0000-0002-4528-3273
Rubenstein, David S. https://orcid.org/0000-0003-0302-8722
Tallman, Anna M. https://orcid.org/0000-0001-9535-0414
-
Funding
Funding for this research was provided by:
Dermavant
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 26 November 2024
First Online: 7 January 2025
Declarations
:
: Eric L. Simpson reports grants and fees for participation as a consultant and principal investigator from Eli Lilly, LEO Pharma, Pfizer, and Regeneron; grants for participation as a principal investigator from Galderma and Merck & Co.; and fees for consultant services from AbbVie, Boehringer Ingelheim, Dermavant Sciences, Inc., Incyte, Forte Bio, Pierre Fabre Dermo, and Sanofi Genzyme. Adelaide A. Hebert has received research support paid to the medical school from AbbVie, Arcutis, Dermavant Sciences, Inc., and Pfizer; has received honoraria from Arcutis, Dermavant Sciences, Inc., Galderma, Incyte, LEO Pharma, Novan, Ortho Dermatologics, Sun Pharma, and Verrica; and has received honoraria as part of Data Safety Monitoring Boards for Alphyn, GSK, Ortho Dermatologics, and Sanofi Regeneron. John Browning has served as an investigator for AbbVie, Acelyrin, Amgen, Arcutis, Dermavant Sciences, Inc., Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, UCB Pharma, and Vyne; and as a speaker for Krystal, Pfizer, and Regeneron. Rocco T. Serrao has served as a consultant and/or has received payment for the development of educational presentations, and/or has received grants from Abbott, AbbVie, Arcutis, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen, Pfizer, Regeneron, and Sanofi-Genzyme. Howard Sofen has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB Biopharma. Philip M. Brown, Stephen C. Piscitelli, and Anna M. Tallman are employees of Dermavant Sciences, an Organon Company, Jersey City, NJ, USA. David S. Rubenstein is a former employee of Dermavant Sciences, Inc.
: Trials were conducted according to Good Clinical Practice and the Declaration of Helsinki. Approval was obtained from all local ethics committees or institutional review boards. All patients (or parents/legal guardians) provided written informed consent.
